Clinical Study

A Phase I/ II Study Of Chemo Radiation Plus The Anti-Pd-1 Antibody, Pembrolizumab (Mk-3475) For Locally Advanced Laryngeal Squamous Cell Carcinoma

Posted Date: Mar 19, 2018

  • Investigator: Vinita Takiar
  • Specialties: Hematology/Oncology, Oncology, Cancer, Radiation Oncology
  • Type of Study: Drug

The purpose of this research study is to test the safety and the benefit of adding pembrolizumab to treatment that you will already be getting for your cancer. Pembrolizumab is a therapy that activates your immune system to fight your cancer.

Criteria:

To Be Eligible For This Study, Patients Must Have Head And Neck Cancer As Well As Post-Operative Radiation And Possibly Cisplatin.

Keywords:

Ucci-Hn-15-02, Anti-Pd-1, Laryngeal Squamous Cell Carcinoma, Cancer, Head And Neck

For More Information:

Uc Cancer Institute
5135847698
kastla@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.